Health

Teneobio

Private Company

TeneoBio, Inc. is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs™), as therapeutics against cancer, autoimmunity, and infectious diseases.

teneobio.com

U.S.

Therapeutics

Leaders
Roland Buelow, Ph.D.

CEO

Ben Buelow, M.D., Ph.D.

Chief Medical Officer

Wim van Schooten, Ph.D.

Chief Scientific Officer

Omid Vafa, Ph.D., MBA

Chief Business Officer

Lightspeed Team
Jonathan MacQuitty

Venture Partner

TeneoBio, Inc. is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs™), as therapeutics against cancer, autoimmunity, and infectious diseases.